Johnson & Johnson will release its Q2 earnings on July 15, with analysts expecting earnings of $2.85 per share and revenue of $25.06 billion, up from last year. Analysts from RBC Capital and TD Cowen have maintained positive ratings and raised price targets amid growing investor interest. The company offers a 2.08% annual dividend yield, and investors can calculate potential monthly income from dividends based on current yields and share prices. Shares recently closed at $257.77, reflecting steady investor confidence ahead of the report.
The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...
Poolbeg Pharma has dosed the first patient in its POLB 001 TOPICAL trial, testing a treatment to prevent cytokine release syndrome in multiple myeloma patients receiving teclistamab. The trial has expanded to University College London Hospital with m...
Last week, US stock markets gained ground with the S&P 500 up 1.2% and Nasdaq Composite rising 1.7%, despite President Trump's announcement that the cease-fire with Iran had ended. Investors appeared to focus on ongoing US-Iran talks rather than the ...
